Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
584 articles about Janssen Pharmaceutical Inc.
-
The partnership with Chinese biotech Cellular Biomedicine Group will cost J&J $245 million upfront and give it access to two differentiated CAR-T therapies for diffuse large B-cell lymphoma. -
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
4/30/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy and cetrelimab monotherapy in patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy.
-
Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
4/21/2023
The Janssen Pharmaceutical Companies announced today that five company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting in New Orleans from April 23-27, 2023.
-
The RSV race has lost one high-profile contender as Janssen announced it is discontinuing the Phase III EVERGREEN trial studying its RSV vaccine candidate. -
Janssen Provides Portfolio Update - March 29, 2023
3/29/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an assessment of the respiratory syncytial virus vaccine landscape, the Company will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study.
-
TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
3/17/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA ® (guselkumab) was associated with greater treatment persistence a compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.
-
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
3/5/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® vascular dose over standard of care, demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD.
-
New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
3/4/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced final pooled long-term safety results for STELARA® through five years in adults with moderately to severely active CD and four years in adults with moderately to severely active UC, as well as final four-year clinical and endoscopic outcomes from the UNIFI LTE study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.
-
TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
3/3/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab.
-
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
3/2/2023
Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc. today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).
-
Janssen Launches Health Equity Campaign in Partnership with Award-Winning Radio Host D.L. Hughley to Raise Awareness About Multiple Myeloma Among Black Communities
3/2/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of That's My Word™ to raise awareness of and help to drive better health outcomes for multiple myeloma among at-risk populations.
-
Janssen Submits New Drug Application to the US FDA Seeking Approval of Niraparib & Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with mCRPC with BRCA Gene Mutations
3/1/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet, plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.
-
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive mCRPC
2/16/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly polymerase inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer with or without specific homologous recombination repair gene alterations, including BRCA mutations.
-
Arrowhead Pharmaceuticals has gained full rights to ARO-PNPLA3, formerly JNJ-75220795, the company announced Wednesday. -
Janssen reported positive topline data from a Phase II proof of concept study assessing nipocalimab in severe hemolytic disease of the fetus and newborn.
-
J&J's Janssen terminated its integrin research collaboration with Morphic Therapeutics. This follows the June 2022 termination of a partnership with AbbVie.
-
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease. -
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
-
In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). -
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.